Panda Pratikeswar, Mohanty Shreyashree, Gouda Sangita Ranee, Mohapatra Rajaram
Department of Pharmaceutics, School of Pharmaceutical Science, Siksha 'O' Anusandhan University, Bhubaneswar, Odisha, India.
J Drug Target. 2025 Jun;33(5):587-611. doi: 10.1080/1061186X.2024.2443144. Epub 2024 Dec 27.
Nanomedicine offers a promising avenue for improving retinal drug delivery, effectively addressing challenges associated with ocular diseases like age-related macular degeneration and diabetic retinopathy. Nanoparticles, with their submicron size and customisable surface properties, enable enhanced permeability and retention within retinal tissues, supporting sustained drug release and minimising systemic side effects. Nanostructured scaffolds further provide a supportive environment for retinal cell growth and tissue regeneration, crucial for treating degenerative conditions. Additionally, advanced nanodevices facilitate real-time monitoring and controlled drug release, marking significant progress in retinal therapy. This study reviews recent advancements in nanomedicine for retinal drug delivery, critically analysing design innovations, therapeutic benefits, and limitations of these systems. By advancing nanotechnology integration in ocular therapies, this field holds strong potential for overcoming current barriers, ultimately improving patient outcomes and quality of life.
纳米医学为改善视网膜药物递送提供了一条有前景的途径，有效应对与年龄相关性黄斑变性和糖尿病视网膜病变等眼部疾病相关的挑战。纳米颗粒具有亚微米尺寸和可定制的表面特性，能够增强在视网膜组织中的渗透性和滞留性，支持药物持续释放并将全身副作用降至最低。纳米结构支架进一步为视网膜细胞生长和组织再生提供支持性环境，这对于治疗退行性疾病至关重要。此外，先进的纳米器件有助于实时监测和控制药物释放，标志着视网膜治疗取得了重大进展。本研究综述了纳米医学在视网膜药物递送方面的最新进展，批判性地分析了这些系统的设计创新、治疗益处和局限性。通过推动纳米技术在眼部治疗中的整合，该领域在克服当前障碍方面具有巨大潜力，最终改善患者的治疗效果和生活质量。
